 Cyclo Therapeutics NASDAQ: CYTH shares are trading higher Tuesday after the company announced positive efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and sales of cyclodextrins CD and related products for food, pharmaceutical, and other industries to be used in diagnostics and specialty drugs with continuing growth in research and new product development. 